Research Papers:
MDI 301, a synthetic retinoid, depressed levels of matrix metalloproteinases and oxidative stress in diabetic dermal fibroblasts
Metrics: PDF 1674 views | HTML 1997 views | ?
Abstract
Jianhua Zhai1 and Yuli Wang2
1Department of Emergency, Tianjin Medical University of General Hospital, Tianjin, China
2Tianjin Institute of Pharmaceutical Research, Tianjin, China
Correspondence to:
Yuli Wang, email: [email protected]
Keywords: diabetic fibroblast cell, high glucose, retinoid acid, MMPs, TIMP1
Received: January 05, 2017 Accepted: March 17, 2017 Published: April 03, 2017
ABSTRACT
Diabetic foot ulcerations could result in serious consequences such as amputations. The up-regulation of matrix metalloproteinases and down-regulation of TIMP1 were remarked as distinctive biological characteristics in the diabetic dermal fibroblast. The current study was performed in order to clarify the effect of high glucose on formation of diabetic dermal fibroblast cell. In addition, the effect of MDI 301 on ameliorating diabetic fibroblasts was investigated in this study. The mRNA and protein expression levels of MMPs, TIMP1 and catalase were evaluated against fibroblasts treated with high glucose (30 mM) using qRT-PCR, western blotting and zymography assays. Methods were also employed for investigating the biological effects of MDI 301 on high glucose-induced diabetic fibroblasts. In this study, we found that the unbalance of oxidative stress induced by high glucose concentration play an important role in the formation of diabetic dermal fibroblast from normal cells. In addition, MDI 301, a picolinic acid-substituted ester of 9-cis retinoic acid was employed in this study in order to ameliorate symptoms on diabetic dermal fibroblast induced by high glucose concentration. We found MDI 301 alleviate the effects of high glucose-induced skin damage by balancing the oxidative stress and regulating the MMPs and TIMP1 levels. Our finding indicated that MDI 301 offers the potential for repairing the faulty skin function arising from diabetes.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16803